Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212605 | 0.82 | PIK3CA (0.46) | KDM4EALDH1A1SMN1; SMN2MMP13NPY5R | |
| SCHEMBL6214063 | 0.80 | MMP13 (0.38) | KMT2AKDM4ECNR2PTGDR2ALDH1A1 | |
| SCHEMBL6213121 | 0.76 | MMP13 (0.49) | KDM4EALDH1A1SMN1; SMN2MMP13PPARG | |
| SCHEMBL6215775 | 0.75 | MMP13 (0.47) | KMT2AKDM4EALDH1A1SMN1; SMN2MMP13 | |
| SCHEMBL6214058 | 0.75 | MMP13 (0.54) | KMT2AMMP13SLC22A8PPARGMEN1 | |
| SCHEMBL6213639 | 0.74 | ALDH1A1 (0.52) | KDM4EALDH1A1SMN1; SMN2MMP13NPY5R | |
| SCHEMBL6211185 | 0.74 | CNR2 (0.49) | KMT2AKDM4ECNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6214009 | 0.73 | PPARG (0.46) | ALDH1A1MMP13PPARG | |
| SCHEMBL6512116 | 0.73 | PPARG (0.41) | PPARG | |
| SCHEMBL6213339 | 0.71 | PIK3CA (0.44) | ALDH1A1MMP13NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362048-B1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER LAMBERT CO (US) | 2005-05-04 | — | — | EP | claimed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | claimed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | claimed |
| EP-1362048-B1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER LAMBERT CO (US) | 2005-05-04 | — | — | EP | disclosed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | CYP26B1 1699/4885NR1H4 2559/4885KMT2A 2962/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | CYP26B1 363/4885NR1H4 1838/4885KMT2A 1264/4885 |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP11, MMP13, MMP10 | CYP26B1 827/4885NR1H4 2510/4885KMT2A 1558/4885 |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | MMP8, MMP13, MMP9 | CYP26B1 627/4885NR1H4 2796/4885KMT2A 2130/4885 |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP11, MMP13, MMP10 | CYP26B1 604/4885NR1H4 2290/4885KMT2A 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.